X

Trial Profile

An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 16 Nov 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GFB 887 (Primary)
Indications Focal segmental glomerulosclerosis; Kidney disorders; Lipoid nephrosis; Nephrosis
Focus Adverse reactions
Sponsors Goldfinch Bio

Most Recent Events

10 Nov 2022 Status changed from recruiting to discontinued.
23 Aug 2022 According to ClinicalTrials.gov record, protocol has been amended to decrease treatment arm from 2 to 1, Study design changed from Parallel Assignment to Single Group Assignment.
10 Aug 2021 According to Goldfinch Bio media release, first patient had been dosed in this study

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com